A Multicentre, Randomised, Double-blind, Placebo-controlled, 2-way Cross-over Study to Evaluate the Efficacy and Safety of CHF 5259 (Glycopyrrolate Bromide) pMDI on Top of QVAR pMDI for the Treatment of Patients With Uncontrolled Asthma on Low-Medium Dose of Inhaled Corticosteroids
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Glycopyrrolate (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms ELITRA
- Sponsors Chiesi Farmaceutici
- 15 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 13 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials
- 05 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.